| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | decitabine | CTRPv2 | pan-cancer | AAC | 0.073 | 0.009 |
| mRNA | BRD-K02251932 | CTRPv2 | pan-cancer | AAC | 0.1 | 0.009 |
| mRNA | BRD-K14844214 | CTRPv2 | pan-cancer | AAC | 0.1 | 0.009 |
| mRNA | JNJ-26854165 | CTRPv2 | pan-cancer | AAC | 0.089 | 0.01 |
| mRNA | BRD-K34222889 | CTRPv2 | pan-cancer | AAC | 0.082 | 0.01 |
| mRNA | ML239 | CTRPv2 | pan-cancer | AAC | 0.092 | 0.01 |
| mRNA | tivozanib | GDSC1000 | pan-cancer | AAC | -0.088 | 0.01 |
| mRNA | Midostaurin | GDSC1000 | pan-cancer | AAC | -0.089 | 0.01 |
| mRNA | Bexarotene | GDSC1000 | pan-cancer | AAC | -0.09 | 0.01 |
| mRNA | selumetinib:MK-2206 (8:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.089 | 0.01 |